Lisa Urquhart
Pharma and Biotech Editor/Writer at Freelance
Freelance pharma and biotech editor/writer, interested in health inequality, pharma AI and drug discovery and development. DM or email me at [email protected]
Articles
-
Oct 3, 2024 |
thepharmaletter.com | Lisa Urquhart
F2G’s September $100m funding round provides the company with crucial funds to renavigate approval of its lead drug, olorofim. The substantial financing also highlights the paucity of novel antifungal products in the clinic. Olorofim is an orotomides, one of the few novel antifungal classes developed in the past 20 years. Olorofim is also the only antifungal project to be awarded a breakthrough therapy designation for multiple indications by the FDA.
-
Jun 13, 2024 |
thepharmaletter.com | Lisa Urquhart
Aardvark Therapeutics might not have scored the biggest venture haul in May, but its $85 million Series C round will further strengthen rumors that the California-based company is gearing up for an initial public offering (IPO) this summer, which could come as soon as late July.
-
May 13, 2024 |
thepharmaletter.com | Lisa Urquhart
At a cool $1 billion, the venture round secured by AI group Xaira ranks as the second-biggest raise in biotech history. In the drug discovery space, this financing is dwarfed only by Altos Lab’s $3 billion, amassed back in 2021. Xaira’s funding success is yet another signal of pharma’s growing interest in AI-led drug discovery.
-
Jul 31, 2023 |
evaluate.com | Lisa Urquhart
Keytruda is the gift that keeps on giving, with the PD-1 checkpoint inhibitor smashing expectations in Merck & Co’s second-quarter earnings; global sales surged 19% to $6.3bn. Merck also reported unexpectedly high sales of the HPV vaccine Gardasil, as huge demand in China pushed sales up by 47% to $2.5bn. Merck added a billion to its full-year sales guidance, taking it to $58.6-59.6bn, and shares in the group responded accordingly, rising 2% this morning before flattening.
-
Jul 27, 2023 |
evaluate.com | Edwin Elmhirst |Lisa Urquhart
While approval for Eisai-partnered Leqembi and expectations around depression treatment Zuranolone have gone someway to raise investor expectations, the group is still facing challenges to its lucrative MS franchise, including potential US biosimilar entries for Tysabri, its current top seller. As such the Reata acquisition could be seen as decisive action to shore up sales until Biogen’s bigger prospects can come online.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 972
- Tweets
- 1K
- DMs Open
- No
RT @ByAmyBrown: Can Enhertu push on the HER2-low door once again? My quick take for @apexonco https://t.co/PnRYjz5Me1 $AZN $DSNKY
RT @ByJoFagg: Good timing for my Pdufa story given the $BIIB $RETA news, Zuranolone's decision is due 5 Aug. Check out the full August tab…
Biogen's Chris Viehbacher $BIIB makes big $7.3bn M&A move for $RETA, but is it too pricey? Mine and @EdwinElmhirst's take via @evaluatevantage https://t.co/DCVqsRxVab